Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Targeted therapy for chronic respiratory disease: a new paradigm

- Featured Image

Targeted therapy represents a new treatment paradigm that shows great promise in treating serious chronic respiratory diseases for which we presently have limited treatment options.1 Pharmacotherapy in the 20th century was best characterised by the use of antibiotics for infectious diseases. An antimicrobial drug targets a specific pathogen which is the cause of an infectious disease, leading to cure. This approach has its basis in Paul Ehrlich’s magic bullet (zauberkugel) theory and his success with a series of specific antimicrobials for syphilis.2 Although highly effective for acute infectious diseases, this approach cannot be usefully applied to non-communicable chronic diseases (NCCDs) because a single aetiological agent cannot be identified.

Step therapy has emerged as the dominant treatment paradigm for NCCDs such as cardiovascular disease (hypertension, congestive cardiac failure), type 2 diabetes mellitus, cancer and chronic airway disease (asthma, chronic obstructive pulmonary disease). In step therapy, drugs are added (step up) or withdrawn (step down) based on the level of responsiveness to treatment. This has led to improved outcomes but is limited. A key limitation is that individual variability in treatment response is ignored in this one-size-fits-all paradigm.

A new concept is to take individual variability into account when making management…

email